Recently, Saiwei Technology, a leading Chinese medical AI company, officially announced the initiation of its Initial Public Offering (IPO) advisory process, marking a critical step toward entering the capital markets. According to public filings, Saiwei has engaged a top-tier securities firm as its sponsor and submitted IPO advisory registration documents to the local securities regulatory bureau. Specializing in AI-powered ophthalmic diagnostics and intelligent medical imaging analysis, Saiwei has developed a proprietary multimodal AI algorithm platform that delivers significant clinical value in early screening for conditions such as diabetic retinopathy and glaucoma. Its solutions are already deployed in hundreds of medical institutions across China. The launch of IPO preparations reflects not only the maturity of the company’s business model and growing profitability but also strong investor interest in the medical AI sector. If the process proceeds smoothly, Saiwei Technology is poised to become the first publicly listed company in China focused specifically on ophthalmic AI, further accelerating the adoption of AI technologies in primary healthcare and chronic disease management.
近日，国内领先的医疗人工智能企业——赛炜科技正式宣布启动首次公开发行（IPO）辅导程序，标志着该公司向登陆资本市场迈出关键一步。据公开信息显示，赛炜科技已与某头部券商签署上市辅导协议，并向地方证监局提交了辅导备案材料。作为专注于眼科AI诊断与智能影像分析的高新技术企业，赛炜科技凭借其自主研发的多模态AI算法平台，在糖尿病视网膜病变、青光眼等眼部疾病的早期筛查领域取得了显著成果，产品已在全国数百家医疗机构落地应用。此次启动IPO辅导，不仅体现了公司业务模式的成熟和持续盈利能力的增强，也反映出资本市场对医疗AI赛道的高度关注。若后续进展顺利，赛炜科技有望成为国内眼科AI领域的首家上市公司，进一步推动人工智能技术在基层医疗和慢病管理中的普及与应用。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/3033.html